Physician profile
Kelsey Ferrell
NPI 1700311974
$6,315.05
in general payments reported to CMS, 2019-2025
32 companies · $489 in 2025
The $489 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $749 · 2021: $939 · 2022: $839 · 2023: $816 · 2024: $729 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.01 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,714.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,117.24 | 2019-2025 | |
| Janssen Biotech, INC. | $829.50 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $463.99 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $329.40 | 2019-2025 | |
| Ucb, INC. | $171.36 | 2020-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $166.33 | 2019-2023 | Dupixent |
| Incyte Corporation | $152.17 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $132.88 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $114.14 | 2019-2023 | Blu-U, Odomzo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $99.86 | 2024 | Sotyktu |
| Allergan, INC. | $97.33 | 2019 | |
| Dermavant Sciences, INC. | $81.54 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.34 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $76.85 | 2023 | Tremfya |
| Vyne Pharmaceuticals INC. | $73.97 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Organon LLC | $61.15 | 2025 | Vtama |
| Organogenesis INC. | $58.52 | 2023-2024 | Puraply |
| Kerecis Limited | $53.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Leo Pharma INC. | $46.10 | 2021-2023 | Adbry |
| Celgene Corporation | $45.98 | 2019 | |
| Biofrontera INC. | $43.63 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.57 | 2024 | Spevigo |
| Blueprint Medicines Corporation | $21.09 | 2022 | |
| Dermira, INC. | $19.14 | 2019 | |
| Amgen INC. | $15.84 | 2020 | |
| Pfizer INC. | $15.27 | 2023 | |
| Arcutis Biotherapeutics, INC. | $14.14 | 2024 | Zoryve |
| Genentech USA, INC. | $14.11 | 2019 | |
| Csl Behring | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.